JENNIFER L. HARRIS

Dynamic leader in clinical development with a proven track record at Sequoia Vaccines, enhancing medical affairs strategy and fostering cross-functional collaboration. Specializes in immunology and oncology, driving strategic planning and business growth. Expert in regulatory affairs with a flair for engaging investigators and managing high-performing teams.

• Perer E, Stacey H, Eichorn T, Hughey H, Lawrence J, Cunningham E, Johnson MO, Bacon K, Kau A, Hultgren SJ, Hooton TM, Harris JL., Case report: Long-term follow-up of patients who received a FimCH vaccine for prevention of recurrent urinary tract infections caused by antibiotic resistant Enterobacteriaceae: a case report series., Front Immunol., 03/13/24, 10.3389/fimmu.2024.1359738, 38545110, PMC10966921
• Harris J, Stocum M, Roberts L, Jiang C, Lin J, Sprott K., Quest for the Ideal Cancer Biomarker: An Update on Progress in Capture and Characterization of Circulating Tumor Cells., Drug Dev Res, 02/13, 10.1002/ddr.21072
• Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL., Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy., J Clin Oncol, 03/01/08
• Kelly H, Graham M, Humes E, Dorflinger LJ, Boggess KA, O’Neil BH, Harris J, Spector NL, Dees EC., Delivery of a healthy baby after first-trimester maternal exposure to lapatinib., Clin Breast Cancer., 10/06
• Xia, W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL., A model of acquired autoresistance to a potent ERbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer., Proce Natl Acad Sci USA, 05/16/06
• Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell, KL, O’Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL., Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases in heavily pretreated patients with metastatic carcinomas., J Clin Oncol., 08/10/05
• Spector NL, Xia W, Burris H, Hurwitz H, Dees EC, Dowlati A, O’Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S., Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies., J Clin Oncol., 04/10/05

• North Carolina Pharmacy License